ABBN.SW: $86.50 ▲ 0.40 (0.46%)ASML.AS: $1,579.80 ▲ 19.00 (1.22%)ENR.DE: $160.76 ▼ -1.74 (-1.07%)GLEN.L: $531.80 ▼ -3.50 (-0.65%)IFX.DE: $81.47 ▲ 0.91 (1.13%)NOKIA.HE: $12.38 ▲ 0.38 (3.17%)RIO.L: $7,259.00 ▼ -5.00 (-0.07%)AMD: $519.85 ▼ -31.78 (-5.76%)INTC: $132.28 ▼ -8.66 (-6.14%)MU: $1,051.77 ▼ -159.61 (-13.18%)WDC: $670.75 ▼ -61.87 (-8.45%)AAPL: $294.30 ▼ -2.71 (-0.91%)AMZN: $234.11 ▲ 1.32 (0.57%)NVDA: $200.04 ▼ -8.61 (-4.13%)AMAT: $585.88 ▼ -54.30 (-8.48%)CIEN: $459.85 ▼ -0.48 (-0.10%)STX: $1,038.59 ▼ -55.45 (-5.07%)

Company Details

Genprex, Inc.

GNPX - NASDAQ

Identifiants & Marche

Ticker GNPX
ISIN US3724462037
CIK 0001595248
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Biotechnology

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Voir l'evolution du cours Retour